The increased activity of the EGF/EGFR complex that is associated with prostate tumour progression leads to the activation of different downstream signalling pathways including MEKK/ERK and PI3K/AKT (Phosphoinositide 3-OH Kinase). This evidence concerns the gene EGFR and prostate neoplasm.